Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

41 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Visit 6 GIMEMA CML0408 NCT00769327 - Visit 6

- 29/11/2017 - 1 Formulário, 2 Grupos de itens, 23 Elementos de dados, 2 Idiomas
Grupos de itens: Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 6 form.

Visit 4 GIMEMA CML0408 NCT00769327 - Visit 4

- 29/11/2017 - 1 Formulário, 2 Grupos de itens, 23 Elementos de dados, 2 Idiomas
Grupos de itens: Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 4 form.

Visit 2 GIMEMA CML0408 NCT00769327 - Visit 2

- 28/11/2017 - 1 Formulário, 3 Grupos de itens, 28 Elementos de dados, 2 Idiomas
Grupos de itens: Physical Examination, NILOTINIB, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 2 form.

Concomitant Therapy GIMEMA CML0408 NCT00769327 - Concomitant Therapy

- 29/11/2017 - 1 Formulário, 1 Grupo de itens, 4 Elementos de dados, 2 Idiomas
Grupo de itens: Concomitant pharmacological therapies
RATIONALE: Nilotinib and imatinib m esylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Concomitant Therapy Form.

Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425 - Baseline Assessments, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

- 27/09/2016 - 1 Formulário, 16 Grupos de itens, 104 Elementos de dados, 1 Idioma
Grupos de itens: Medical and Surgical History, Significant Medical and Surgical History, NSCLC Diagnosis, NSCLC-related Surgery, Tobacco/Nicotine History at Randomization, Prior Adjuvant Chemotherapy, Prior Adjuvant Chemotherapy for NSCLC, Optional Research Blood Sample, Radiology, Vital Assessment, Physical Examination, Pregnancy Test, Hematology, Biochemistry/Proteomics, Study Drug Dispensed, Investigator's Signature
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Baseline Assessments

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial